Plaque Debulking Prior to Stenting Dr. Layth A. Mimish The Cardiovascular Consultants Group Jeddah, Saudi Arabia.

Slides:



Advertisements
Similar presentations
Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.
Advertisements

Dr Sandeep Mohanan SR Cardiology Calicut Medical College JOURNAL REVIEW.
Calcified vessels – balloons that cut Azfar Zaman Freeman Hospital, Newcastle-upon-Tyne.
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
Four Drug Eluting Stent Trials Keith D Dawkins MD FRCP FACC Southampton University Hospital Keith D Dawkins MD FRCP FACC Southampton University Hospital.
A PROSPECTIVE MULTICENTRE REGISTRY FOR THE ASSESSMENT OF SAFETY AND EFFICACY OF BIODEGRADABLE POLYMER COATED, PACLITAXEL ELUTING STENT LUC TM * *(BALTON,
ARTS I & II Keith D Dawkins Southampton University Hospital.
Optimal Management of ACS Invasive vs Conservative Strategy
AVE Micro Stent KFSH & RC Experience with 6 months Angiographic Follow Up Layth A. Mimish, M. Bakhshi, F. Al-Nozha, A. Kinsara, O. Amoudi, J. Buraiki,
Layth Ahmad Mimish Consultant Cardiologist The Cardiovascular Consultants Group Jeddah, KSA.
Complications of HSRA Layth A. Mimish Consultant Cardiologist Cardiovascular Consultants Group Jeddah, Saudi Arabia.
Directional Coronary Atherectomy KFSH & RC Experience Layth A. Mimish, J. Buraiki, M. E. Fawzy, B. Dunn, M. Bakhshi, B. Dajani.
30 th Annual Meeting of The Egyptian Society of Cardiology.
Left Main Coronary Artery Dissection Complicating Diagnostic Coronary Angiography Layth A. Mimish MBChB, FRCPC, FACC Medical Director The Cardiovascular.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides
As presented by Patrick W. Serruys, MD, PhD, FACC Principal Investigator Thoraxcentre - Erasmus University Rotterdam, The Netherlands PISCES Paclitaxel.
VULNERABLE PLAQUES: Pertinent doubts and solutions in interventional cardiology EuroPCR Paris, 16 May 2006.
ICE Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Dr Adrian Banning, The John Radcliffe, Oxford Drug eluting stents for in-stent restenosis.
Trial Vignettes Contemporary trials 3: DES
Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts,
PCI in Left Main Coronary Bifurcation Disease -Step Mini Crush
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
As presented by Keith D Dawkins MD FRCP FACC Southampton University Hospital United Kingdom EuroSTAR The European Cobalt Stent with Antiproliferative for.
One patient, two years, three choices, four PCI ZHAO Peng Cardiology ， the Affiliated Hospital of Medical College of CPAPF, Tianjin, China.
When I Use IVUS Neal Uren MD FRCP Consultant Cardiologist Royal Infirmary Edinburgh.
Rapamycin- and Paclitaxel-Eluting Stents With Identical Biodegradable Polymeric Coating and Design Trial Presented at The American College of Cardiology.
MassMedic Presentation Innovation Accelerated SM.
AICT 2010-Athens Interventional Cardiovascular Therapeutics XI 8-9 OCTOBER 2010 Divani Caravel Hotel, Αthens EARLY CLINICAL OUTCOMES AFTER PROMUS ELEMENT.
Radiation for restenosis: the dark side of arteries Robert S Schwartz MD Professor of Medicine Mayo Clinic Rochester, MN.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
Social Roles and Relationships.
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Www. Clinical trial results.org Cypher sirolimus-eluting stent Primary Endpoint:  In-stent and late lumen loss at 9 months (determined by QCA) Secondary.
Early and Late Stent Thrombosis Rates in 5,054 Real-World Patients from XIENCE V USA With and Without Dual Antiplatelet Therapy Interruptions James Hermiller,
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
R4 하 상 진. Introduction Circulation May 1;115(17):
Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention Lisette Okkels Jensen,
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Paradigm shifts in cardiovascular medicine J Am.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
DRug Eluting Bbsorbable Metal Scaffold (DREAMS)
Successful transdradial removal of a dislodged coronary stent
Tubular LMS stenosis. LCx ostial stenosis
Layth A. Mimish, M. Bakhshi, J. Buraiki,
(DES)+BVS +DCB for long diffuse LAD disease
The Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel
Crossing SFA-Popliteal Artery CTO’s
The Winking Saphenous Vein Graft: Acute Aorto-Vein Graft Anastomotic Torsional Kink causing Dynamic Systolic Compression Complicating Vein Graft PCI Dr.
Instent Restenosis and Occlusion: Time for Surgical Revision?
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
Stenting of Coronary Arteries in Non Stress/Benestent Disease
SIRIUS Trial: Diameter Restenosis
Angiography-guided PCI
EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.
Kyoto University Hospital, Japan
Main branch restenosis at 1 year
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.
A late complication of internal carotid artery stenting
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
American College of Cardiology Presented by Dr. Adnan Kastrati
The American College of Cardiology Presented by Dr. A. Abazid
Presentation transcript:

Plaque Debulking Prior to Stenting Dr. Layth A. Mimish The Cardiovascular Consultants Group Jeddah, Saudi Arabia

The Role of Plaque Burden in Non-Stent Interventions

The Relationship Between Residual Plaque Burden Post Stenting and Neo-Intimal Hyperplasia

Site of Restenosis (STOP Trial)

Debulking

Quantitative Angiography (SOLD Registry)

IVUS Measurements

Procedural & In-Hospital Complications SOLD Registry

Restenosis & TLR (SOLD Registry)

Location of Restenosis

Plaque Area & Restenosis

Debulking / Stenting Attenuates Late Loss in Response to Acute Gain

Is it All Debulking Effect

Is This Debulking

TLR Rates in Trials According To Better Debulking

How Aggressive Should Debulking Be ?

START Trial

Debulking / Stenting in Ostial LAD lesions

DCA / Stenting For Ostial Lesions

Debulking Ostial Lesions

CTO

LM Disease

Newer Debulking Devices

Design Goals

Flexicut

Instent Restenosis

HSRA For Instent Restenosis

Laser For Instent Restenosis

DCA

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.